-

Agilent Included in Just Capital’s 2023 List of Most Just Companies

Ranking Underscores Agilent’s Strong Performance on Issues of Greatest Importance to Americans

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC. Agilent also earned the top ranking in its sector for industry-leading performance regarding treatment of employees, customers and the environment.

Just Capital and CNBC based the rankings on a review of the policies and practices of 1,000 of the largest U.S. public companies on issues that matter most to Americans, including wages and benefits, job creation, worker health and safety, ethical leadership, and environmental stewardship.

Agilent’s top ranking on worker issues reflects its commitment to being an employer of choice globally. In 2022, Agilent earned Great Place to Work® Certification in 20 countries and regions, including the United States, and was recently ranked among the best workplaces in health care by Fortune.

Just Capital also ranked Agilent number one in the industry for its treatment of customers. For the past two years, Agilent has ranked in the top five in customer satisfaction by the Wall Street Journal and the Drucker Institute’s annual list of the best-managed companies.

“Agilent employees work closely with our customers to bring great science to life and to carry out our mission to advance the quality of life,” said Neil Rees, Agilent’s head of Environmental, Social, and Governance (ESG) Programs. “Treating our employees well and creating products that help our customers improve human health and reduce environmental impact are essential to our ESG commitment.”

Agilent has reported on its corporate responsibility practices for over 20 years. The company is included in the JUST U.S. Large Cap Diversified (JULCD) Index and the Dow Jones Sustainability Indices (DJSI). Read more about Agilent’s commitment to net-zero emissions, diversity and inclusion, and other ESG initiatives.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom